Axplora, a global provider of API small molecule manufacturing, announced a significant investment at its Vizag site in India to expand production capacity and reinforce supply chain resilience. This announcement follows the successful completion of routine U.S. FDA inspections in 2025 at both of Axplora’s Indian manufacturing sites, Vizag and Chennai, which form part of the company’s PharmaZell Business Unit. 

The expansion project at Vizag will increase output and create new employment opportunities, enhancing Axplora’s ability to meet growing global demand for high-value pharmaceutical ingredients.

The Vizag and Chennai sites completed routine inspections by the U.S. FDA in 2025, each concluding with a Voluntary Action Indicated (VAI) classification. 

The inspector at the Chennai facility highlighted the strong and consistent implementation of current Good Manufacturing Practices (cGMP), streamlined and efficient document management and retrieval processes, and the standards maintained in facility upkeep and overall site hygiene.

With enhanced capacity at Vizag and regulatory compliance across both sites, Axplora continues to solidify its presence in India and its role as a partner for the global pharmaceutical industry.